Postgrad LIVE! Study Fairs

Birmingham | Edinburgh | Liverpool | Sheffield | Southampton | Bristol

University of East Anglia Featured PhD Programmes
Imperial College London Featured PhD Programmes
Imperial College London Featured PhD Programmes
University of Hong Kong Featured PhD Programmes
Birkbeck, University of London Featured PhD Programmes
"hypertension"×
10 miles

hypertension PhD Projects, Programs & Scholarships

We have 33 hypertension PhD Projects, Programs & Scholarships

  • "hypertension" ×
  • clear all
Order by 
Showing 1 to 10 of 33
  Resistant Hypertension – pathological insights from cardiac microvascular perfusion and mechanics.
  Dr D Oxborough, Prof K George, Prof GYH Lip
Applications accepted all year round
Hypertension commonly predisposes to many cardiovascular complications, including atrial fibrillation, heart failure and stroke. Importantly the heart is responsible for blood pressure yet suffers the consequences of uncontrolled hypertension.
  Translation of Cardiovascular Control Models: Are ‘resistant hypertension’ patients truly drug resistant and does neuronal dysregulation contribute?
  Dr R Barrett-Jolley, Prof GYH Lip, Dr A Shantsila
Applications accepted all year round
Hypertension is major health problem across the world affecting 30-40% of adults, and its prevalence continues to grow, especially in developing countries.
  MRC Precision Medicine DTP: Uromodulin in hypertension and renal dysfunction - causal inference, mechanistic and clinical translation studies for precision medicine
  Research Group: Institute of Cardiovascular and Medical Sciences
  Prof S Padmanabhan, Dr T Van Agtmael
Application Deadline: 7 January 2019
Supervisors. Prof Sandosh Padmanabhan. Dr Tom Van Agtmael. PhD project summary. Genome wide association identified a novel pathway for hypertension and renal function involving uromodulin.
  Regulation of SOX17 by HOXa5: a therapeutic target in pulmonary arterial hypertension
  Dr C Rhodes, Prof M Wilkins, Prof J Ferrer, Dr I Cebola
Application Deadline: 31 January 2019
Applications are invited for a BHF 4 year MRes/PhD studentship starting in October 2019 at the Imperial Centre for Translational and Experimental Medicine (ICTEM), Hammersmith Campus.
  Two pore channel segment 2: a new partner in crime for mTORC1 in pulmonary hypertension
  Prof A M Evans
Applications accepted all year round
Mechanistic target of Rapamycin (mTOR) and regulatory protein of TOR (Raptor) complexes (mTORC1) promote idiopathic- and hypoxic pulmonary hypertension (PH), facilitating pulmonary arterial smooth muscle cell (PASMC) growth, proliferation, and thus pulmonary vascular remodelling.
  MRC DiMeN Doctoral Training Partnership: Identifying inhibitors specific to the OPG-kinome: towards novel treatments for Pulmonary Arterial Hypertension (PAH)
  Dr A Lawrie, Dr R Thompson
Application Deadline: 21 January 2019
Pulmonary arterial hypertension (PAH) is a fatal progressive disease with a median life expectancy of 2.8 years, untreated.
  Study of the osmopressor response in human volunteers with and without hypertension
  Dr M Carew, Dr H Moir
Applications accepted all year round
The osmopressor response refers to the increase in blood pressure and associated change in heart rate that occurs in some people after ingestion of water (1).
  Re-purposing established drugs for the resolution of pulmonary arterial hypertension (PAH)
  Research Group: Pharmacology and Experimental Therapeutics
  Dr T Nasim, Prof T Palmer
Applications accepted all year round
Pulmonary arterial hypertension (PAH) is a devastating cardiovascular disorder which, if left untreated, leads to heart failure and death.
  Therapeutic resolution of pulmonary arterial hypertension (PAH) by natural products
  Research Group: Pharmacology and Experimental Therapeutics
  Dr T Nasim, Prof C Wright
Applications accepted all year round
Pulmonary arterial hypertension (PAH) is a devastating cardiovascular disorder which, if left untreated, leads to heart failure and death.
  MRC Precision Medicine DTP: Estrogenic profiling in lung in Pulmonary Arterial Hypertension by Mass Spectrometry Imaging
  Research Group: Centre for Cardiovascular Science
  Prof R Andrew, Prof M MacLean
Application Deadline: 7 January 2019
Background. Pulmonary Arterial Hypertension (PAH) is a progressive and deadly disease leading to right heart failure, lacking effective treatment.
Show 10 15 30 per page


FindAPhD. Copyright 2005-2018
All rights reserved.